Neumedicines, U.S. Department of Health and Human Services (HHS) other news
Neumedicines said HHS's Biomedical Advanced Research and Development Authority (BARDA) notified the company that BARDA intends to exercise its option for the continued development of HemaMax to treat hematopoietic syndrome of acute radiation sickness. The company said the goal of the option is to conduct animal studies to compare and evaluate the efficacy of HemaMax with G-CSF. Neumedicines said the study will also fulfill one of FDA's requirements for BLA submission - a bridging study to evaluate the efficacy of HemaMax with Level 1 supportive care, which consists of antibiotics and fluids. In 2011, Neumedicines received a $17 million contract from BARDA for HemaMax, a recombinant IL-12. The company declined to disclose the amount received as a result of BARDA's decision to exercise the option. Prior to the exercise of the option, the company had received $33 million from BARDA to develop HemaMax (see BioCentury, Oct. 3, 2011). ...